

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-3 (Cancelled)

Claim 4 (Previously Presented) Purified human tissue factor fragment expressed from a nucleotide molecule encoding a tissue factor selected from the group consisting of tissue factor having an amino acid sequence as provided in Figure 2 from at least amino acid residue one to at least amino acid residue 219, and human tissue factor having an amino acid sequence as provided in Figure 2 from at least amino acid residue one to at least amino acid residue 219 wherein an amino acid residue at an N- or O-glycosylation site is substituted, wherein the tissue factor has activity in a clotting assay with human plasma.

Claim 5' (Previously Presented) The tissue factor fragment of claim 4 wherein the nucleotide molecule does not encode the transmembrane domain defined by amino acids 220 to 243 as provided in Figure 2.

Claim 6 (Previously Presented) The tissue factor fragment of claim 4 wherein the nucleotide molecule encodes a tissue factor having an amino acid sequence as provided in Figure 2 from amino acid residue one to amino acid residue 219.

Claim 7 (Cancelled)

Claim 8 (Previously Presented) The tissue factor fragment of claim 4 expressed in a recombinant non-human host cell.

Claims 9-19 (Cancelled)

Claim 20 (Previously Presented) A soluble isolated tissue factor fragment expressed from a nucleotide molecule encoding tissue factor in a recombinant non-human host cell, the tissue factor having the amino acid sequence shown in Figure 2 from amino

acid one to an amino acid residue between amino acid residues 219 and amino acid residue 263, wherein the tissue factor has activity in a clotting assay.

Claim 21 (Previously Presented) The tissue factor fragment of claim 20 which is not glycosylated.

Claim 22 (Cancelled)

Claim 23 (Previously Presented) The tissue factor fragment of claim 20 having an amino acid sequence of Figure 2 from between amino acid one and between residues 220 and 263.

Claim 24 (Previously Presented) The tissue factor fragment of claim 20 wherein the cysteine residues are substituted with other amino acids.

Claim 25 (Previously Presented) The tissue factor fragment of claim 20 wherein the potential proteolysis sites are deleted by replacing the amino acids with glutaminy or histidyl residues or deleting one of the basic residues.

Claim 26 (Cancelled)

Claim 27 (Previously Presented) The human tissue factor fragment of claim 20 expressed in a host cell selected from the group consisting of procaryotic cells, non-human animal cells, insect cells, plant cells, and yeast, having activity in a clotting assay.

Claim 28 (Previously Presented) The human tissue factor fragment of claim 27 which is not glycosylated.

Claims 29-30 (Cancelled)

Claim 31 (Previously Presented) Recombinant human tissue factor fragment expressed from a nucleotide sequence encoding an amino acid sequence comprising from amino acid residue one to amino acid residue 219 as provided in Figure 2, wherein the tissue factor protein has activity in a clotting assay with human plasma.

Claim 32 (Previously Presented) The recombinant human tissue factor fragment of claim 31 wherein the nucleotide sequence does not encode the transmembrane domain of human tissue factor.

Claim 33 (Previously Presented) The recombinant human tissue factor fragment of claim 32 wherein the nucleotide sequence does not encode the amino acid sequence from amino acid residue 220 to amino acid residue 243 as provided in Figure 2.

Claim 34 (Previously Presented) The recombinant human tissue factor fragment of claim 31 which is not glycosylated.

Claim 35 (Previously Presented) The recombinant human tissue factor fragment of claim 31 which is expressed in a host cell selected from the group consisting of procaryotic cells, non-human animal cells, insect cells, plant cells, and yeast.

Claim 36 (Previously Presented) The recombinant human tissue factor fragment of claim 31 which includes an heterologous amino or carboxyl terminal fusion.

Claim 37 (Cancelled)

Claim 38 (Previously Presented) The recombinant tissue factor fragment of claim 31 wherein the cysteine residues are substituted with other amino acids.

Claim 39 (Previously Presented) The recombinant tissue factor fragment of claim 31 wherein the potential proteolysis sites are deleted by replacing the amino acids with glutaminy or histidyl residues or deleting one of the basic residues.

Claim 40 (Previously Presented) The recombinant tissue factor fragment of claim 31 wherein a residue at an N- or O-glycosylation site is substituted or deleted.

Claim 41 (Previously Presented) Recombinant human tissue factor fragment comprising an amino acid sequence from amino acid residue one to amino acid residue 219 as provided in Figure 2, wherein the tissue factor protein has activity in a clotting assay with human plasma.

Claim 42 (Previously Presented) A recombinant soluble human tissue factor protein, wherein said tissue factor protein is produced by a process comprising deleting the transmembrane domain, which transmembrane domain comprises amino acid residues 220 to 242, from full length human tissue factor protein having the amino acid sequence set forth in Figure 2 from amino acid residue one to 263.

Claim 43 (Previously Presented) A recombinant soluble human tissue factor protein wherein the transmembrane domain is deleted, further wherein full length human tissue factor protein has an amino acid sequence as provided in Figure 2 from amino acid residue one to 263, and said transmembrane domain is located at amino acid residues 220 to 242.

Claim 44 (Previously Presented) A recombinant soluble human tissue factor protein having the amino acid sequence from residue one to 219 as shown in Figure 2.

Claim 45 (Previously Presented) A recombinant soluble human tissue factor protein.

Claim 46 (Previously Presented) An isolated DNA molecule encoding a soluble human tissue factor protein lacking the transmembrane binding domain, wherein the transmembrane binding domain comprises amino acid residues 220 to 242 and full length human tissue factor protein has the amino acid sequence set forth in Figure 2 from amino acid residue one to 263.

Claim 47 (Previously Presented) An isolated DNA molecule encoding a soluble human tissue factor protein wherein the transmembrane domain has been deleted.

Claim 48 (New) A recombinant soluble human tissue factor protein wherein the transmembrane domain is deleted, having amino acid residue one to amino acid residue 219 and amino acid residue 243 to amino acid residue 263 as provided in Figure 2.

Claim 49 (New) A recombinant soluble human tissue factor protein as set forth in Figure 2, wherein the transmembrane domain is deleted at about amino acid residues 220 to 242.

Claim 50 (New) An isolated DNA molecule encoding a soluble human tissue factor protein wherein the transmembrane domain is deleted, said soluble tissue factor protein having amino acid residue one to amino acid residue 219 and amino acid residue 243 to amino acid residue 263 as provided in Figure 2.

Claim 51 (New) An isolated DNA molecule encoding a soluble human tissue factor protein as set forth in Figure 2, wherein the transmembrane domain is deleted at about amino acid residues 220 to 242.